C-MYC–Positive Relapsed and Refractory DLBCL and Outcomes With Subsequent Therapy.
Patients with diffuse large B-cell lymphoma (DLBCL) who failed to achieve complete remission or relapsed ≤6 months after chemoimmunotherapy were analyzed to evaluate the response to salvage therapy and subsequent outcomes. The overall response rate to salvage therapy was 51% in an MYC-negative cohort, 50% in an MYC-positive single hit (SH) cohort, and 54% in […]
C-MYC–Positive Relapsed and Refractory DLBCL and Outcomes With Subsequent Therapy. Read More »
